Therapeutics: RAD52 homolog (RAD52); breast cancer 1 early onset (BRCA1); BRCA2
Cancer
INDICATION: Cancer; leukemia
In vitro studies identified 6-hydroxy-DL-dopa as an allosteric inhibitor of RAD52 that could
Gathering data...
INDICATION: Cancer; leukemia
In vitro studies identified 6-hydroxy-DL-dopa as an allosteric inhibitor of RAD52 that could